Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2026 earnings per share estimates for shares of Edgewise Therapeutics in a report released on Monday, December 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of ($1.91) for the year, up from their prior estimate of ($2.04). The consensus estimate for Edgewise Therapeutics' current full-year earnings is ($1.45) per share.
EWTX has been the subject of a number of other reports. Wedbush increased their price objective on shares of Edgewise Therapeutics from $44.00 to $45.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Royal Bank of Canada reiterated an "outperform" rating and issued a $32.00 price target on shares of Edgewise Therapeutics in a research note on Tuesday, September 17th. Truist Financial boosted their price objective on Edgewise Therapeutics from $33.00 to $50.00 and gave the company a "buy" rating in a research report on Wednesday, November 27th. Piper Sandler increased their target price on Edgewise Therapeutics from $48.00 to $51.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Finally, Evercore ISI lifted their target price on Edgewise Therapeutics from $45.00 to $50.00 and gave the company an "outperform" rating in a research note on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $43.17.
Read Our Latest Stock Analysis on EWTX
Edgewise Therapeutics Trading Up 2.6 %
NASDAQ EWTX traded up $0.79 on Thursday, reaching $30.80. 876,724 shares of the stock were exchanged, compared to its average volume of 941,088. Edgewise Therapeutics has a one year low of $8.49 and a one year high of $38.12. The firm has a market capitalization of $2.92 billion, a PE ratio of -20.53 and a beta of 0.12. The company's 50-day simple moving average is $32.83 and its two-hundred day simple moving average is $24.47.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.01.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the business. Sofinnova Investments Inc. purchased a new stake in shares of Edgewise Therapeutics during the second quarter valued at $8,567,000. Federated Hermes Inc. purchased a new stake in Edgewise Therapeutics in the 2nd quarter valued at about $833,000. Ally Bridge Group NY LLC bought a new position in Edgewise Therapeutics in the 3rd quarter worth about $5,010,000. abrdn plc purchased a new position in shares of Edgewise Therapeutics during the third quarter worth approximately $6,850,000. Finally, Novo Holdings A S bought a new stake in shares of Edgewise Therapeutics during the second quarter valued at approximately $114,263,000.
Insider Activity
In other news, CMO Joanne M. Donovan sold 7,162 shares of the firm's stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $28.29, for a total value of $202,612.98. Following the completion of the sale, the chief marketing officer now owns 14,538 shares in the company, valued at approximately $411,280.02. This trade represents a 33.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO R Michael Carruthers sold 125,092 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $28.57, for a total transaction of $3,573,878.44. Following the completion of the sale, the chief financial officer now directly owns 6,904 shares in the company, valued at $197,247.28. This trade represents a 94.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 278,176 shares of company stock worth $7,893,316. 24.11% of the stock is currently owned by insiders.
About Edgewise Therapeutics
(
Get Free Report)
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Further Reading
Before you consider Edgewise Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.
While Edgewise Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
